Aldeyra Therapeutics (ALDX) Non-Current Assets (2013 - 2026)
Aldeyra Therapeutics (ALDX) posted Non-Current Assets of $209262.0 for Q1 2026, down 24.14% on a QoQ basis from $275861.0 in Q4 2025, and down 55.18% year-over-year from $466942.0 in Q1 2025.
Aldeyra Therapeutics (ALDX) Non-Current Assets (2013 - 2026) Analysis & Trends
Aldeyra Therapeutics' Non-Current Assets history runs 14 years deep, the most recent figure standing at $209262.0 for Q1 2026.
- Quarterly Non-Current Assets fell 55.18% year-over-year to $209262.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (down 38.28% YoY) and the FY2025 annual result came in at $275861.0, down 48.36% from the prior year.
- Non-Current Assets was $209262.0 for Q1 2026 at Aldeyra Therapeutics, down from $275861.0 in the prior quarter.
- Across five years, Non-Current Assets topped out at $598589.0 in Q3 2024 and bottomed at $72233.0 in Q3 2023.
- A 5-year average of $335139.4 and a median of $337926.0 in 2022 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2023 — Non-Current Assets tumbled 65.37% — and 2024, when it jumped 728.69%.
- Aldeyra Therapeutics' Non-Current Assets stood at $268544.0 in 2022, then soared by 92.36% to $516578.0 in 2023, then grew by 3.41% to $534216.0 in 2024, then slumped by 48.36% to $275861.0 in 2025, then retreated by 24.14% to $209262.0 in 2026.
- Business Quant data shows ALDX's Non-Current Assets at $209262.0 in Q1 2026, $275861.0 in Q4 2025, and $340977.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,140.12 Bn | 66,139.83 Bn | - | 21.65 Mn |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | 5.83 Mn |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | 30.30 Mn |
| 4 | BeOne Medicines | 471.41 Bn | 466.62 Bn | 1.35 Bn | 1.95 Bn |
| 5 | Vertex Pharmaceuticals | 122.15 Bn | 114.90 Bn | 2.59 Bn | 14.75 Bn |
| 6 | Regeneron Pharmaceuticals | 69.94 Bn | 61.18 Bn | 3.31 Bn | 22.66 Bn |
| 7 | Belite Bio | 62.43 Bn | 62.43 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 55.85 Bn | 50.67 Bn | 1.41 Bn | 1.96 Bn |
| 9 | Alnylam Pharmaceuticals | 37.48 Bn | 34.47 Bn | 959.66 Mn | 910.24 Mn |
| 10 | Aldeyra Therapeutics | 93.80 Mn | 93.80 Mn | - | 209,262.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 209,262.00 |
| Dec 31, 2025 | 275,861.00 |
| Sep 30, 2025 | 340,977.00 |
| Jun 30, 2025 | 404,660.00 |
| Mar 31, 2025 | 466,942.00 |
| Dec 31, 2024 | 534,216.00 |
| Sep 30, 2024 | 598,589.00 |
| Jun 30, 2024 | 394,315.00 |
| Mar 31, 2024 | 455,946.00 |
| Dec 31, 2023 | 516,578.00 |
| Sep 30, 2023 | 72,233.00 |
| Jun 30, 2023 | 137,232.00 |
| Mar 31, 2023 | 201,572.00 |
| Dec 31, 2022 | 268,544.00 |
| Sep 30, 2022 | 208,603.00 |
| Jun 30, 2022 | 273,914.00 |
| Mar 31, 2022 | 337,926.00 |
| Dec 31, 2021 | 384,350.00 |
| Sep 30, 2021 | 445,621.00 |
| Jun 30, 2021 | 166,484.00 |